Streetbeat News

Revenues

ABBV

AbbVie has updated its sales outlook, projecting combined sales for Skyrizi and Rinvoq to exceed $27 billion by 2027. Additionally, the company has raised its peak sales forecast for Ubrelvy and Qulipta, expecting them to collectively surpass $3 billion.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:41 pm

ABBV

AbbVie has reaffirmed its expectation for a high single-digit compound annual revenue growth rate (CAGR) through 2029, indicating confidence in its long-term financial performance.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:40 pm

AAPL

Apple, Inc. (AAPL) reported fiscal year 2024 first-quarter earnings with a mixed outcome, leading to a nearly 3% drop in premarket trading despite surpassing consensus estimates. The company faced challenges in China with a 12.9% revenue decline and issued soft guidance for the March quarter, impacting investor sentiment.

Portfolio Pulse from Shanthi Rexaline

February 02, 2024 | 12:39 pm

CBOE

Cboe Global Markets has provided its financial guidance for the fiscal year 2024, expecting organic net revenue growth of 5%-7%, and 7%-10% growth specifically from Data and Access Solutions. Adjusted operating expenses are anticipated to be $798M-$808M, with capital expenditures projected at $51M-$57M. Other financial forecasts include a depreciation and amortization expense of $43M-$47M, excluding amortization of acquired intangible assets, and a $37M-$43M benefit from minority investments. The effective tax rate is expected to be between 28.5% and 30.5%.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:34 pm

CHD

Church & Dwight anticipates a 4-5% increase in both reported and organic sales growth for 2024, with an adjusted EPS growth of 7-9%. For Q1, the company expects around 4% growth in reported and organic sales, with an adjusted EPS of $0.85, which is below the estimated $0.93.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:04 pm

BMY

Bristol-Myers Squibb (BMY) forecasts its 2024 adjusted EPS to be in the range of $7.10-$7.40, surpassing the consensus estimate of $7.08. The company expects total 2024 revenues to increase by low single-digits, with a similar increase excluding foreign exchange impacts. Non-GAAP gross margin is anticipated to be around 74%, and non-GAAP operating expenses are also expected to rise by low single-digits.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:04 pm

CHD

Church & Dwight has updated its Evergreen Model, now forecasting a 4% organic net sales growth, up from the previous 3%, while maintaining its target for 8% annual EPS growth.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:01 pm

JHG

Analysts have mixed views on Janus Henderson Group (NYSE:JHG), with recent ratings ranging from indifferent to bearish. Over the last three months, there's been a shift towards a more neutral stance. The average 12-month price target for JHG has been raised to $28.2, indicating a positive sentiment shift. Janus Henderson Group, offering investment management services, has shown a revenue growth of 1.58% as of September 30, 2023, but lags in net margin and ROE compared to industry averages. Its financial structure is deemed sound, with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 12:00 pm

BR

Broadridge Financial Solutions (NYSE:BR) has received mixed analyst ratings over the past three months, with a shift towards a more bullish outlook in the last 30 days. The average 12-month price target for BR has increased by 5.03% to $209.0, with recent analyst actions including raised price targets and ratings. Broadridge, known for its investor communications and technology-driven solutions, has shown strong financial health with notable revenue growth, net margin, ROE, and ROA, despite challenges in debt management.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 12:00 pm

HOLX

Analyst ratings for Hologic (NASDAQ:HOLX) show mixed sentiments with a recent shift towards bullishness. The average 12-month price target is now $80.5, down from $83.50. Analysts from Needham, UBS, Morgan Stanley, and RBC Capital have adjusted their ratings and price targets, reflecting changes in market dynamics and Hologic's performance. Hologic, focusing on women's healthcare, faces challenges in market capitalization, revenue growth, net margin, ROE, ROA, and debt management compared to industry averages.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 12:00 pm